Grupos de investigación

  1. Portada
  2. Publicaciones
  3. Publicaciones 1998-2000

Publicaciones 1998-2000

Publicaciones anteriores

  1. “Receptors and transcriptional factors involved in the anti-inflammatory activity of VIP and PACAP”. Leceta J, Gomariz RP, Martínez C, Abad C, Ganea D, Delgado M. Ann N Y Acad Sci. 2000;921:92-102.
  2. “VIP and PACAP induce shift to a Th2 response by upregulating B7.2 expression”. Delgado M, Leceta J, Sun W, Gomariz RP, Ganea D. Ann N Y Acad Sci. 2000;921:68-78.
  3. “Anti-inflammatory actions of VIP/PACAP. Role in endotoxemia”. Gomariz R, Leceta J, Martínez C, Abad C, Ganea D, Delgado M. Ann N Y Acad Sci. 2000;921:284-8.
  4. “Anti-inflammatory properties of the type 1 and type 2 vasoactive intestinal peptide receptors: role in lethal endotoxic shock”. Delgado M, Gomariz RP, Martínez C, Abad C, Leceta J. Eur J Immunol. 2000 Nov;30(11):3236-46.
  5. “Immunobiology of vasoactive intestinal peptide (VIP)”. Pozo D, Delgado M, Martínez M, Guerrero JM, Leceta J, Gomariz RP, Calvo JR. Immunol Today. 2000 Jan;21(1):7-11. Erratum in: Immunol Today 2000 Apr;21(4):191.
  6. “Different domains of the VIP receptors modulate agonist affinity and intrinsic activity”. Juarranz MG, Van Rampelbergh J, Gourlet P, Waelbroeck M, Robberecht P. Ann N Y Acad Sci. 2000;921:395-9.
  7. “Expression of vasoactive intestinal peptide (VIP) receptors in human uterus”. Bajo AM, Juarranz MG, Valenzuela P, Martínez P, Prieto JC, Guijarro LG. Peptides. 2000 Sep;21(9):1383-8.
  8.  “Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition”. Van Rampelbergh J, Juarranz MG, Perret J, Bondue A, Solano RM, Delporte C, De Neef P, Robberecht P, Waelbroeck M. Br J Pharmacol. 2000 Jun;130(4):819-26.
  9.  “VIP and PACAP38 modulate cytokine and nitric oxide production in peritoneal macrophages and macrophage cell lines”. Delgado M, Muñoz-Elías EJ, Martínez C, Gomariz RP, Ganea D. Ann N Y Acad Sci. 1999;897:401-14.
  10. “VIP and PACAP differentially regulate the costimulatory activity of resting and activated macrophages through the modulation of B7.1 and B7.2 expression”. Delgado M, Sun W, Leceta J, Ganea D. J Immunol. 1999 Oct 15;163(8):4213-23.
  11.  “Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide”. Delgado M, Leceta J, Abad C, Martínez C, Ganea D, Gomariz RP. J Neuroimmunol. 1999 Sep 1;99(1):61-71.
  12. “Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide stimulate the induction of Th2 responses by up-regulating B7.2 expression”. Delgado M, Leceta J, Gomariz RP, Ganea D. J Immunol. 1999 Oct 1;163(7):3629-35. PDF
  13. “Regulation of VIP production and secretion by murine lymphocytes”. Martínez C, Delgado M, Abad C, Gomariz RP, Ganea D, Leceta J. J Neuroimmunol. 1999 Jan 1;93(1-2):126-38.
  14. “VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells”. Delgado M, Muñoz-Elías EJ, Gomariz RP, Ganea D. J Neuroimmunol. 1999 May 3;96(2):167-81.
  15. “Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation”. Delgado M, Muñoz-Elías EJ, Gomariz RP, Ganea D. J Immunol. 1999 Apr 15;162(8):4685-96. PDF
  16. “Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies”. Delgado M, Pozo D, Martínez C, Leceta J, Calvo JR, Ganea D, Gomariz RP. J Immunol. 1999 Feb 15;162(4):2358-67. PDF
  17. “Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies”. Delgado M, Muñoz-Elías EJ, Gomariz RP, Ganea D. J Immunol. 1999 Feb 1;162(3):1707-16. PDF
  18. “Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6”. Delgado M, Martínez C, Pozo D, Calvo JR, Leceta J, Ganea D, Gomariz RP. J Immunol. 1999 Jan 15;162(2):1200-5. PDF
  19. “Vasoactive intestinal peptide in thymus: synthesis, receptors and biological actions”. Delgado M, Martínez C, Leceta J, Gomariz RP. Neuroimmunomodulation. 1999 Jan-Apr;6(1-2):97-107.
  20. “Different vasoactive intestinal polypeptide receptor domains are involved in the selective recognition of two VPAC(2)-selective ligands”. Juarranz MG, Van Rampelbergh J, Gourlet P, De Neef P, Cnudde J, Robberecht P, Waelbroeck M. Mol Pharmacol. 1999 Dec;56(6):1280-7.
  21. “Evidence for multiple rat VPAC1 receptor states with different affinities for agonists”. Busto R, Juarranz MG, De Maria S, Robberecht P, Waelbroeck M. Cell Signal. 1999 Sep;11(9):691-6.
  22. “Vasoactive intestinal polypeptide VPAC1 and VPAC2 receptor chimeras identify domains responsible for the specificity of ligand binding and activation”. Juarranz MG, Van Rampelbergh J, Gourlet P, De Neef P, Cnudde J, Robberecht P, Waelbroeck M. Eur J Biochem. 1999 Oct 1;265(1):449-56.
  23. “Vasoactive intestinal polypeptide receptor VPAC(1) subtype is predominant in rat prostate membranes”. Juarranz MG, De Neef P, Robberecht P. Prostate. 1999 Sep 15;41(1):1-6.
  24. “Effects of chronic ethanol ingestion on the vasoactive intestinal peptide receptor-effector system from rat seminal vesicle membranes”. Juarranz MG, Marinero MJ, Bodega G, Prieto JC, Guijarro LG. Alcohol Clin Exp Res. 1999 Feb;23(2):318-23.
  25. “G-protein regulation of adenylate cyclase activity in rat prostatic membranes after chronic ethanol ingestion”. Juarranz MG, Guijarro LG, Bodega G, Prieto JC. Prostate. 1998 Sep 1;36(4):226-34.
  26. “Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit tumor necrosis factor alpha transcriptional activation by regulating nuclear factor-kB and cAMP response element-binding protein/c-Jun”. Delgado M, Muñoz-Elías EJ, Kan Y, Gozes I, Fridkin M, Brenneman DE, Gomariz RP, Ganea D. J Biol Chem. 1998 Nov 20;273(47):31427-36. PDF
  27. “VIP and PACAP enhance IL-6 release and mRNA levels in resting peritoneal macrophages: in vitro and in vivo studies”. Martínez C, Delgado M, Pozo D, Leceta J, Calvo JR, Ganea D, Gomariz RP. J Neuroimmunol. 1998 May 15;85(2):155-67.
  28. “Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages”. Martínez C, Delgado M, Pozo D, Leceta J, Calvo JR, Ganea D, Gomariz RP. J Leukoc Biol. 1998 May;63(5):591-601. PDF